17 / 43
ORR AND PFS: IMDC FAVORABLE RISK
a
11% of patients in both arms had tumor PD-L1 expression ≥1%
b
IRRC-assessed by RECIST v1.1
c
IRRC-assessed
N = 249
a
Outcome
NIVO + IPI
N = 125
SUN
N = 124
Confirmed ORR,
b
% (95% CI)
29 (21–38)
52 (43–61)
P
= 0.0002
PFS,
c
median (95% CI), months
15.3 (9.7–20.3)
25.1 (20.9–NE)
HR (99.1% CI) 2.18 (1.29–3.68)
P
< 0.0001
Exploratory endpoint
Escudier B, et al. ESMO 2017; LBA5